Page 2204 - Williams Hematology ( PDFDrive )

2178 Part XII: Hemostasis and Thrombosis Chapter 126: von Willebrand Disease 2179

145. Ginsburg D, Bockenstedt PL, Allen EA, et al: Fine mapping of monoclonal antibody 174. Davies JA, Collins PW, Hathaway LS, Bowen DJ: Von Willebrand factor: Evidence for
epitopes on human von Willebrand factor using a recombinant peptide library. Thromb variable clearance in vivo according to Y/C1584 phenotype and ABO blood group.
Haemost 67:166–171, 1992. J Thromb Haemost 6:97–103, 2008.
146. Mazurier C: Von Willebrand disease masquerading as haemophilia A. Thromb Haemost 175. Keeney S, Grundy P, Collins PW, Bowen DJ: C1584 in von Willebrand factor is neces-
67:391–396, 1992. sary for enhanced proteolysis by ADAMTS13 in vitro. Haemophilia 13:405–408, 2007.
147. Lollar P, Hill-Eubanks DC, Parker CG: Association of the factor VIII light chain with 176. Desch KC, Ozel AB, Siemieniak D, et al: Linkage analysis identifies a locus for plasma
von Willebrand Factor. J Biol Chem 263:10451–10455, 1988. von Willebrand factor undetected by genome-wide association. Proc Natl Acad Sci U S A
148. Leyte A, van Schijndel HB, Niehrs C, et al: Sulfation of Tyr 1680 of human blood coagula- 110:588–593, 2013.
tion factor VIII is essential for the interaction of factor VIII with von Willebrand factor. 177. Castaman G, Eikenboom JC, Bertina RM, Rodeghiero F: Inconsistency of association
J Biol Chem 266:740–746, 1991. between type 1 von Willebrand disease phenotype and genotype in families identified
149. Shiltagh N, Kirkpatrick J, Cabrita LD, et al: Solution structure of the major factor VIII in an epidemiological investigation. Thromb Haemost 82:1065–1070, 1999.
binding region on von Willebrand factor. Blood 123:4143–4151, 2014. 178. Kunicki TJ, Federici AB, Salomon DR, et al: An association of candidate gene haplo-
150. National Heart Lung and Blood Institute (NHLBI): The Diagnosis, Evaluation, and Man- types and bleeding severity in von Willebrand disease (VWD) type 1 pedigrees. Blood
agement of von Willebrand Disease. National Institutes of Health, Bethesda, MD, 2007. 104:2359–2367, 2004.
151. Sadler JE, Budde U, Eikenboom JC, et al: Update on the pathophysiology and classi- 179. Kunicki TJ, Baronciani L, Canciani MT, et al: An association of candidate gene haplo-
fication of von Willebrand disease: A report of the Subcommittee on von Willebrand types and bleeding severity in von Willebrand disease type 2A, 2B, and 2M pedigrees.
Factor. J Thromb Haemost 4:2103–2114, 2006. J Thromb Haemost 4:137–147, 2006.
152. Flood VH, Friedman KD, Gill JC, et al: No increase in bleeding identified in type 1 180. Mohlke KL, Purkayastha AA, Westrick RJ, et al: Mvwf, a dominant modifier of murine
VWD subjects with D1472H sequence variation. Blood 121:3742–3744, 2013. von Willebrand factor, results from altered lineage-specific expression of a glycosyl-
153. Johnsen JM, Auer PL, Morrison AC, et al: Common and rare von Willebrand factor transferase. Cell 96:111–120, 1999.
(VWF) coding variants, VWF levels, and factor VIII levels in African Americans: The 181. McKinnon TA, Chion AC, Millington AJ, et al: N-linked glycosylation of VWF modu-
NHLBI Exome Sequencing Project. Blood 122:590–597, 2013. lates its interaction with ADAMTS13. Blood 111:3042–3049, 2008.
154. Wang QY, Song J, Gibbs RA, et al: Characterizing polymorphisms and allelic diversity of 182. O’Donnell JS, McKinnon TA, Crawley JT, et al: Bombay phenotype is associated with
von Willebrand factor gene in the 1000 Genomes. J Thromb Haemost 11:261–269, 2013. reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis.
155. Flood VH, Gill JC, Morateck PA, et al: Common VWF exon 28 polymorphisms in Blood 106:1988–1991, 2005.
African Americans affecting the VWF activity assay by ristocetin cofactor. Blood 116: 183. Bowen DJ: An influence of ABO blood group on the rate of proteolysis of von Wille-
280–286, 2010. brand factor by ADAMTS13. J Thromb Haemost 1:33–40, 2003.
156. Weiss HJ, Piétu G, Rabinowitz R, et al: Heterogeneous abnormalities in the multim- 184. Gallinaro L, Cattini MG, Sztukowska M, et al: A shorter von Willebrand factor sur-
eric structure, antigenic properties, and plasma-platelet content of factor VIII/von vival in O blood group subjects explains how ABO determinants influence plasma von
Willebrand factor in subtypes of classic (type I) and variant (type IIA) von Willebrand’s Willebrand factor. Blood 111:3540–3545, 2008.
disease. J Lab Clin Med 101:411–425, 1983. 185. Casari C, Lenting PJ, Wohner N, et al: Clearance of von Willebrand factor. J Thromb
157. Hoyer LW, Rizza CR, Tuddenham EG, et al: Von Willebrand factor multimer patterns Haemost 11 Suppl 1:202–211, 2013.
in von Willebrand’s disease. Br J Haematol 55:493–507, 1983. 186. Zimmerman TS, Abildgaard CF, Meyer D: The factor VIII abnormality in severe von
158. Mannucci PM, Lombardi R, Bader R, et al: Heterogeneity of type I von Willebrand Willebrand’s disease. N Engl J Med 301:1307–1310, 1979.
disease: Evidence for a subgroup with an abnormal von Willebrand factor. Blood 66: 187. Ngo KY, Glotz VT, Koziol JA, et al: Homozygous and heterozygous deletions of the von
796–802, 1985. Willebrand factor gene in patients and carriers of severe von Willebrand Disease. Proc
159. Mannucci PM: Platelet von Willebrand factor in inherited and acquired bleeding disor- Natl Acad Sci U S A 85:2753–2757, 1988.
ders. Proc Natl Acad Sci U S A 92:2428–2432, 1995. 188. Peake IR, Liddell MB, Moodie P, et al: Severe type III von Willebrand’s disease caused
160. Haberichter SL, Balistreri M, Christopherson P, et al: Assay of the von Willebrand by deletion of exon 42 of the von Willebrand factor gene: Family studies that identify
factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with carriers of the condition and a compound heterozygous individual. Blood 75:654–661,
decreased VWF survival. Blood 108:3344–3351, 2006. 1990.
161. Bowman M, Tuttle A, Notley C, et al: The genetics of Canadian type 3 von Willebrand 189. Mancuso DJ, Tuley EA, Castillo R, et al: Characterization of partial gene deletions
disease: Further evidence for co-dominant inheritance of mutant alleles. J Thromb in type III von Willebrand disease with alloantibody inhibitors. Thromb Haemost 72:
Haemost 11:512–520, 2013. 180–185, 1994.
162. Goodeve A, Eikenboom J, Castaman G, et al: Phenotype and genotype of a cohort of 190. Xie F, Wang X, Cooper DN, et al: A novel Alu-mediated 61-kb deletion of the von
families historically diagnosed with type 1 von Willebrand disease in the European Willebrand factor (VWF) gene whose breakpoints co-locate with putative matrix
study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 attachment regions. Blood Cells Mol Dis 36:385–391, 2006.
von Willebrand Disease (MCMDM-1VWD). Blood 109:112–121, 2007. 191. Cabrera N, Casaña P, Cid AR, et al: First application of MLPA method in severe von
163. Robertson JD, Yenson PR, Rand ML, et al: Expanded phenotype-genotype correla- Willebrand disease. Confirmation of a new large VWF gene deletion and identification
tions in a pediatric population with type 1 von Willebrand disease. J Thromb Haemost of heterozygous carriers. Br J Haematol 152:240–242, 2011.
9:1752–1760, 2011. 192. Nichols WC, Lyons SE, Harrison JS, et al: Severe von Willebrand disease due to a
164. Eikenboom J, Hilbert L, Ribba AS, et al: Expression of 14 von Willebrand factor defect at the level of von Willebrand factor mRNA expression: Detection by exonic
mutations identified in patients with type 1 von Willebrand disease from the MCMD- PCR-restriction fragment length polymorphism analysis. Proc Natl Acad Sci U S A 88:
M-1VWD study. J Thromb Haemost 7:1304–1312, 2009. 3857–3861, 1991.
165. Wang JW, Valentijn KM, de Boer HC, et al: Intracellular storage and regulated secre- 193. Eikenboom JC, Ploos van Amstel HK, Reitsma PH, Briët E: Mutations in severe, type
tion of von Willebrand factor in quantitative von Willebrand disease. J Biol Chem III von Willebrand’s disease in the Dutch population: Candidate missense and non-
286:24180–24188, 2011. sense mutations associated with reduced levels of von Willebrand factor messenger
166. Pruss CM, Golder M, Bryant A, et al: Pathologic mechanisms of type 1 VWD muta- RNA. Thromb Haemost 68:448–454, 1992.
tions R1205H and Y1584C through in vitro and in vivo mouse models. Blood 117: 194. Nichols WC, Ginsburg D: Von Willebrand disease. Medicine (Baltimore) 76:1–20, 1997.
4358–4366, 2011. 195. Ginsburg D, Sadler JE: Von Willebrand Disease: A database of point mutations, inser-
167. Millar CM, Riddell AF, Brown SA, et al: Survival of von Willebrand factor released tions, and deletions. Thromb Haemost 69:177–184, 1993.
following DDAVP in a type 1 von Willebrand disease cohort: Influence of glycosylation, 196. Eikenboom JC, Castaman G, Vos HL, et al: Characterization of the genetic defects in
proteolysis and gene mutations. Thromb Haemost 99:916–924, 2008. recessive type 1 and type 3 von Willebrand disease patients of Italian origin. Thromb
168. Mohlke KL, Ginsburg D: Von Willebrand disease and quantitative deficiency of von Haemost 79:709–717, 1998.
Willebrand factor. J Lab Clin Med 130:252–261, 1997. 197. Zhang ZP, Falk G, Blombäck M, et al: A single cytosine deletion in exon 18 of the
169. Eikenboom JC, Matsushita T, Reitsma PH, et al: Dominant type 1 von Willebrand dis- von Willebrand factor gene is the most common mutation in Swedish vWD type III
ease caused by mutated cysteine residues in the D3 domain of von Willebrand factor. patients. Hum Mol Genet 1:767–768, 1992.
Blood 88:2433–2441, 1996. 198. Zhang ZP, Blombäck M, Nyman D, Anvret M: Mutations of von Willebrand factor gene
170. Bodo I, Katsumi A, Tuley EA, et al: Type 1 von Willebrand disease mutation Cys- in families with von Willebrand disease in the Åland Islands. Proc Natl Acad Sci U S A
1149Arg causes intracellular retention and degradation of heterodimers: A possi- 90:7937–7940, 1993.
ble general mechanism for dominant mutations of oligomeric proteins. Blood 98: 199. Mohlke KL, Ginsburg D: Von Willebrand disease and quantitative deficiency of von
2973–2979, 2001. Willebrand factor. J Lab Clin Med 130:252–261, 1997.
171. O’Brien LA, James PD, Othman M, et al: Founder von Willebrand factor haplotype 200. Schneppenheim R, Krey S, Bergmann F, et al: Genetic heterogeneity of severe von
associated with type 1 von Willebrand disease. Blood 102:549–557, 2003. Willebrand disease type III in the German population. Hum Genet 94:640–652,
172. Bowen D: Type 1 von Willebrand disease: A possible novel mechanism. Blood Coagul 1994.
Fibrinolysis 15 Suppl 1:S21–S23, 2004. 201. Mohlke KL, Ginsburg D: Von Willebrand disease and quantitative deficiency of von
173. Bowen DJ, Collins PW, Lester W, et al: The prevalence of the cysteine1584 variant of Willebrand factor. J Lab Clin Med 130:252–261, 1997.
von Willebrand factor is increased in type 1 von Willebrand disease: Co-segregation 202. Berkowitz SD, Dent JA, Roberts J, et al: Epitope mapping of the von Willebrand factor
with increased susceptibility to ADAMTS13 proteolysis but not clinical phenotype. subunit distinguishes fragments present in normal and type IIA von Willebrand Dis-
Br J Haematol 128:830–836, 2005. ease from those generated by plasmin. J Clin Invest 79:524–531, 1987.

Kaushansky_chapter 126_p2163-2182.indd 2179 9/21/15 3:15 PM